NCT03258554 · OUTCOME

Change in EuroQol 5 Dimension 5 Level (EQ 5D 5L) Index Score at One Year

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin · Source last updated 2026-08-27

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline and 1 year

What was measured

The EQ-5D-5L Index score measures health related quality of life based on responses to five dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Possible scores range from 0 (worst health state) to 1(best health state). Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The EQ-5D-5L Index score measures health related quality of life based on responses to five dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Possible scores range from 0 (worst health state) to 1(best health state). Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.
reporting Status: NOT_POSTED
time Frame: Baseline and 1 year
title: Change in EuroQol 5 Dimension 5 Level (EQ 5D 5L) Index Score at One Year
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice